NCT03075111

Brief Summary

This is a retrospective external field study of a novel in vitro diagnostic (IVD) assay (ImmunoXpert™). The study will involve reviewing the medical charts of about 4500 pediatric patients that were tested using ImmunoXpert™ as part of the routine workup for acute febrile illness. ImmunoXpert™ uses a computer algorithm to combine immunoassay measurements of three host immune proteins (TRAIL, IP-10, and CRP) present in human blood. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. Statistical analysis will be performed to compare the diagnostic accuracy of ImmunoXpert™ with that of current practice lab testing e.g., WBC, CRP, and PCT (whichever were taken as part of routine care) and clinical suspicion at time of requisition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2015

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 7, 2015

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

March 6, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 9, 2017

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2019

Completed
3.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 5, 2022

Completed
Last Updated

August 4, 2022

Status Verified

August 1, 2022

Enrollment Period

3.2 years

First QC Date

March 6, 2017

Last Update Submit

August 2, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The sensitivity and specificity of a host-response based diagnostics in differentiating between bacterial and viral etiology of patients with an acute febrile disease.

    0-7 days after the initiation of symptoms

Secondary Outcomes (1)

  • The sensitivity and specificity of a host-response based diagnostics in differentiating between infectious and non-infectious disease etiology

    0-7 days after the initiation of symptoms

Interventions

ImmunoXpertDIAGNOSTIC_TEST

Host based immune response test distinguishing viral versus bacterial infection

Eligibility Criteria

Age3 Months - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

1. Patients with an acute bacterial infection 2. Patients with an acute viral infection 3. Patients with an acute co-infection (bacterial and viral) 4. Patients with an undetermined disease etiology

You may qualify if:

  • Patients aged 3 month to 18 years that were admitted due to acute febrile illness, and ImmunoDx test was taken as part of their workup.
  • The febrile illness should also fulfill the following criteria:
  • The patient had a peak temperature ≥38°C (AND)
  • Symptoms initiated ≤ 7 days before sampling (AND)
  • A retrospective diagnosis of bacterial or viral or mixed infection was anonymously determined by a panel of three independent senior pediatricians.
  • The non-infectious disease control group will include:
  • A retrospective diagnosis of a non-infectious disease was anonymously determined by a panel of three independent senior pediatricians physicians.
  • Patients with a non-infectious disease ( and ImmunoDx test was wrongly taken)

You may not qualify if:

  • Samples from patients who had one or more of the following criteria will be excluded from the study:
  • Another infection episode during the last 3 weeks before sampling
  • Congenital immune deficiency (CID)
  • A proven or suspected HIV-1, HBV, HCV infection
  • Active hematological malignancy
  • Current treatment with immune-suppressive or immune-modulating therapies including without limitations:
  • Use of high dose steroids \>1 mg/kg/day prednisone or equivalent in the last two weeks
  • Monoclonal antibody administration
  • Intravenous immunoglobulin (IVIG)
  • Other illnesses that affect life expectancy and/or quality of life
  • Suspicion of gastrointestinal infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hillel Yaffe Medical center

Hadera, Israel

Location

Bnei Zion medical center

Haifa, 31048, Israel

Location

Related Publications (1)

  • Klein A, Shapira M, Lipman-Arens S, Bamberger E, Srugo I, Chistyakov I, Stein M. Diagnostic Accuracy of a Real-Time Host-Protein Test for Infection. Pediatrics. 2023 Dec 1;152(6):e2022060441. doi: 10.1542/peds.2022-060441.

Biospecimen

Retention: NONE RETAINED

Serum and plasma samples

MeSH Terms

Conditions

Fever

Condition Hierarchy (Ancestors)

Body Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 6, 2017

First Posted

March 9, 2017

Study Start

November 7, 2015

Primary Completion

February 1, 2019

Study Completion

July 5, 2022

Last Updated

August 4, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations